- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02543710
Biomarker Guided Treatment in Gynaecological Cancer (Momatec2)
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series.
Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers.
Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
연구 개요
상태
정황
연구 유형
등록 (예상)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Jone Trovik, MD PhD Prof
- 전화번호: +4755974200
- 이메일: jone.trovik@k2.uib.no
연구 연락처 백업
- 이름: Henrica MJ Werner, MD PhD MRCOG
- 전화번호: +4755974200
- 이메일: henrica.werner@k2.uib.no
연구 장소
-
-
-
Nijmegen, 네덜란드
- 아직 모집하지 않음
- Radboud University Hospital
-
연락하다:
- Hanny MA Pijnenborg, MD, PhD
-
연락하다:
- Casper Reijne, MD
-
-
-
-
-
Alesund, 노르웨이, 6017
- 모병
- Ålesund Hospital
-
연락하다:
- Margaret S Lode, MD
-
Førde, 노르웨이, 6812
- 모병
- Førde Central Hospital
-
연락하다:
- Jostein Tjugum, MD
-
연락하다:
- marthe LT Larsson, MD
-
Kristiansand, 노르웨이, 4604
- 아직 모집하지 않음
- Sørlandet hospital
-
연락하다:
- Ane C Munk, MD, PhD
-
연락하다:
- ingvild Vistad, MD, PhD
-
Oslo, 노르웨이
- 모병
- Akershus University Hospital
-
연락하다:
- marie E Engh, MD
-
Stavanger, 노르웨이, 4011
- 모병
- Stavanger University Hospital
-
연락하다:
- Elisabeth B Nilsen, MD
-
Trondheim, 노르웨이, 7006
- 모병
- St Olav University Hospital
-
연락하다:
- Nina Nordskar, MD
-
연락하다:
- Solveig Tingulstad, MD
-
-
Hordaland
-
Bergen, Hordaland, 노르웨이, 5053
- 모병
- Women's hospital, Haukeland university hospital
-
연락하다:
- Henrica MJ Werner, MD, PhD
- 전화번호: +4755974200
- 이메일: heaw@helse-bergen.no
-
연락하다:
- Jone Trovik, prof MD PhD
- 전화번호: +4755974200
- 이메일: jone.trovik@uib.no
-
-
-
-
-
Lublin, 폴란드, 20-081
- 모병
- Spsk No 1
-
연락하다:
- Bartolomiej Barczynski, MD, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria part 1:
All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
Exclusion Criteria part 1:
- Patients who do not have endometrial cancer
- Patients who will or cannot give informed consent (including language barriers)
- Patients <18 years of age
- Patients who will not get surgical treatment for their endometrial cancer
Inclusion criteria part 2:
- Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.
- Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.
Exclusion criteria part 2:
- Patients not suffering from endometrial or epithelial ovarian cancer
- Patients <18 years of age
- Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre
- Patients who cannot or do not want to give informed consent (including language barriers)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: phase 4 implementation study
The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm.
These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding.
Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
|
Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR). Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy. Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure. Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up. |
|
실험적: phase 2b biomarker study
For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
|
A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start. During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
number of recurrences after primary treatment
기간: 5 year after diagnosis
|
The percentage of lymphadenectomy can be reduced safely and significantly, from 70% (MoMaTEC1 study results) to 30% in the MoMaTEC2 study through a better risk stratification of patients, especially better identification of low risk patients.
Additionally The percentage of patients who need to be subjected to adjuvant (chemo) therapy can be reduced similarly from 20 to 10%, based on the same, optimised risk stratification and better identification of low risk patients.
Patients will be rigorously followed during 5 years to detect any unexpected increase in the percentage of patients suffering a recurrence compared to the historical MoMaTEC1 cohort.
|
5 year after diagnosis
|
|
stathmin levels
기간: duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
stathmin level will be measured in metastatic tissue and related to response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria
|
duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quality of life measurements
기간: 5 years post treatment
|
Quality of life will be measured through validated questionnaires (EORTC QLQ-C30 and EORTC QLQ-EN24).
|
5 years post treatment
|
|
correlation of stathmin llevels in tumor, urine and blood
기간: duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
stathmin tumor levels, urine levels and blood levels will be correlated.
|
duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Henrica MJ Werner, MD PhD MRCOG, Haukeland University Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .